Zhao-Chong Zeng1, Jinsil Seong2, Sang Min Yoon3, Jason Chia-Hsien Cheng4, Ka-On Lam5, Ann-Shing Lee6, Ada Law7, Jian-Ying Zhang1, Yong Hu1. 1. Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. 2. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea. 3. Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 4. Department of Radiation Oncology, National Taiwan University Hospital, Taipei, Taiwan. 5. Department of Clinical Oncology, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China. 6. Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, SAR, China. 7. Department of Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, SAR, China.
Abstract
BACKGROUND: Stereotactic body radiation therapy (SBRT) is an advanced technique of external beam radiation therapy that delivers large ablative doses of radiation. In the past decade, many cancer centers have adopted SBRT as one mode of radically treating small-sized hepatocellular carcinoma (HCC), based on encouraging clinical outcomes. SBRT thus seems reasonable as first-line treatment of inoperable HCC confined to the liver. However, most of the clinical studies to date have been retrospective in nature, with key issues still under investigation. SUMMARY: The above-mentioned publications were subjected to scrutiny, fueling discussions at the 7th Asia-Pacific Primary Liver Cancer Expert (APPLE 2016) Meeting on various clinical variables, such as indications for SBRT, therapeutic outcomes, treatment-related toxicities, doses prescribed, and specific techniques. The consensus reached should be of interest to all professionals active in the treatment of HCC, especially radiation oncologists. KEY MESSAGES: SBRT is a safe and effective therapeutic option for patients with small-sized HCC, offering substantial local control, improved overall survival, and low toxicity.
BACKGROUND: Stereotactic body radiation therapy (SBRT) is an advanced technique of external beam radiation therapy that delivers large ablative doses of radiation. In the past decade, many cancer centers have adopted SBRT as one mode of radically treating small-sized hepatocellular carcinoma (HCC), based on encouraging clinical outcomes. SBRT thus seems reasonable as first-line treatment of inoperable HCC confined to the liver. However, most of the clinical studies to date have been retrospective in nature, with key issues still under investigation. SUMMARY: The above-mentioned publications were subjected to scrutiny, fueling discussions at the 7th Asia-Pacific Primary Liver Cancer Expert (APPLE 2016) Meeting on various clinical variables, such as indications for SBRT, therapeutic outcomes, treatment-related toxicities, doses prescribed, and specific techniques. The consensus reached should be of interest to all professionals active in the treatment of HCC, especially radiation oncologists. KEY MESSAGES: SBRT is a safe and effective therapeutic option for patients with small-sized HCC, offering substantial local control, improved overall survival, and low toxicity.
Authors: Robert B Case; Jan-Jakob Sonke; Douglas J Moseley; John Kim; Kristy K Brock; Laura A Dawson Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-21 Impact factor: 7.038
Authors: Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Eun Kyung Paik; Mi-Sook Kim; Won Il Jang; Young Seok Seo; Chul-Koo Cho; Hyung Jun Yoo; Chul Ju Han; Su Cheol Park; Sang Bum Kim; Young Han Kim Journal: Radiat Oncol Date: 2016-02-19 Impact factor: 3.481
Authors: Kimberly L Shampain; Caitlin E Hackett; Sohrab Towfighi; Anum Aslam; William R Masch; Alison C Harris; Silvia D Chang; Kanika Khanna; Vivek Mendiratta; Ahmed M Gabr; Dawn Owen; Mishal Mendiratta-Lala Journal: Abdom Radiol (NY) Date: 2021-05-07
Authors: Mishal Mendiratta-Lala; William R Masch; Kimberly Shampain; Andrew Zhang; Alexandria S Jo; Sarah Moorman; Anum Aslam; Katherine E Maturen; Matthew S Davenport Journal: Radiol Imaging Cancer Date: 2020-01-31
Authors: Tom Tan-To Cheung; Philip Chong-Hei Kwok; Stephen Chan; Chin-Cheung Cheung; Ann-Shing Lee; Victor Lee; Hoi-Ching Cheng; Nam-Hung Chia; Charing C N Chong; Tak-Wing Lai; Ada L Y Law; Mai-Yee Luk; Chi Chung Tong; Thomas C C Yau Journal: Liver Cancer Date: 2018-01-25 Impact factor: 11.740